Medicare AdvantageCoverageMedium impact
MA08.021c, Dofetilide (Tikosyn®) Use in the Inpatient Setting
Independence Blue Cross·Cardiology, Critical Care, Internal Medicine·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of the MA08.021c policy governing Dofetilide (Tikosyn®) use in inpatient settings. This policy establishes coverage and utilization requirements for this antiarrhythmic medication in hospital-based care for Medicare Advantage plans. Billing teams must ensure claims for inpatient dofetilide administration comply with the specific criteria outlined in this policy.
Action Required
By April 1, 2026: Billing team must review the complete MA08.021c policy text to identify specific coverage criteria, prior authorization requirements, and documentation standards for inpatient dofetilide claims. Update billing software edits and claim scrubbing rules to enforce any prior auth or medical necessity documentation requirements. Communicate policy requirements to inpatient facilities and cardiology departments. Train billing staff on claim denial reasons related to non-compliance. Since the full policy content is not provided in this analysis, obtain the complete policy document from the URL provided and extract specific clinical criteria, required documentation fields, and any authorization processes before the effective date.